The new ICH Q13 guideline is almost here! The guideline on continuous manufacturing (CM) is currently in Step 5, implementation.
We, as ValGenesis, have been actively involved on the public consultation phase. And, because of that, we thought of talking a bit about it.
What is the Timeline?
The final version of ICH Q13 arrives in July 2023.
What Will be in it?
The guideline covers several points all connected to Continuous Manufacturing. Specifically, it looks at the scientific and regulatory perspective for the development, implementation and lifecycle management of drug substances and drug products.
And it also does this from two perspectives: new products and the transition of existing products from batch to CM.
A Much Needed Clarification
This guideline is so important because it bring a much needed clarification to CM. And what does it clarify?
First of all, it specifies the different CM modes. That is, the difference between Hybrid, CM or integrated CM modes of setting up production.
It bridges the batch definition of ICH Q7 by providing advice on control strategy, production output and continuous process verification.
The guideline also supports the process description by complementing the ICH M4Q so that it covers CM processes.
It covers Control strategy with relevant controls and approaches used during manufacturing.
Last, but not the least, it also covers both batch description and the conversion of a batch process into CM.
A Handful of Supplements
The guideline is not only full of the important information we pointed before. It also includes a set of annexes that cover:
- Drug substances (DS) for chemical entities
- Drug Products (DP)
- Therapeutic Protein DS
- Integrated DP and DS
- Perspectives on managing disturbances
Can we Help Your CM Transformation?
Our team is specialized in delivering Continuous Manufacturing Implementation and Support. If you’d like to move towards the benefits of Continuous Manufacturing, take a look at our services!
